Jørgensen N R, Henriksen Z, Sørensen O H, Civitelli R
Osteoporosis and Bone Metabolic Unit, Copenhagen University Hospital Hvidovre, Kettdgaard Allé 30, Hvidovre DK-2650, Denmark.
Steroids. 2004 Apr;69(4):219-26. doi: 10.1016/j.steroids.2003.12.005.
In vitro models of bone cells are important for the study of bone biology, including the regulation of bone formation and resorption. In this study, we have validated an in vitro model of human osteoblastic cells obtained from bone marrow biopsies from healthy, young volunteers, aged 20-31 years. Osteoblast phenotypes were induced by either dexamethasone (Dex) or bone morphogenetic protein-2 (BMP-2). Bone marrow was obtained from biopsies at the posterior iliac spine. Cells were isolated by gradient centrifugation and grown to confluence. Cells were treated with 1 nM 1,25-dihydroxyvitamin D (vitamin D), 100 nM Dex, and/or 100 ng/ml BMP-2. The osteoblast phenotype was assessed as alkaline phosphatase (AP) activity/staining, production of osteocalcin and procollagen type 1 (P1NP), parathyroid hormone (PTH)-induced cyclic adenosine mono-phosphate (cAMP) production, and in vitro mineralization. AP activity was increased by Dex, but not by BMP-2 treatment. P1NP production was decreased after Dex treatment, while BMP-2 had no effect on P1NP levels. Osteocalcin production was low in cultures not stimulated with vitamin D. Dex or BMP-2 treatment alone did not affect the basic osteocalcin levels, but in combination with vitamin D, BMP-2 increased the osteocalcin production, while Dex treatment completely suppressed osteocalcin production. Further, PTH-induced cAMP production was greatly enhanced by Dex treatment, whereas BMP-2 did not affect cAMP production. Finally, in vitro mineralization was greatly enhanced in cultures enriched with either BMP-2 or Dex. Cell proliferation was only increased significantly by Dex treatment. In conclusion, the model described produces cells with an osteoblastic phenotype, and both Dex and BMP-2 can be used as osteoblast inducers. However, the two treatments produce osteoblastic cells with different phenotypic characteristics, and a selective activation of some of the most important genes and functions of the mature osteoblast can thus be performed in vitro.
骨细胞的体外模型对于骨生物学研究非常重要,包括骨形成和吸收的调节。在本研究中,我们验证了一种从20 - 31岁健康年轻志愿者的骨髓活检中获得的人成骨细胞体外模型。通过地塞米松(Dex)或骨形态发生蛋白-2(BMP-2)诱导成骨细胞表型。骨髓取自髂后上棘的活检组织。通过梯度离心分离细胞并培养至汇合。细胞用1 nM 1,25 - 二羟基维生素D(维生素D)、100 nM Dex和/或100 ng/ml BMP-2处理。通过碱性磷酸酶(AP)活性/染色、骨钙素和I型前胶原(P1NP)的产生、甲状旁腺激素(PTH)诱导的环磷酸腺苷(cAMP)产生以及体外矿化来评估成骨细胞表型。Dex可增加AP活性,但BMP-2处理则无此作用。Dex处理后P1NP产生减少,而BMP-2对P1NP水平无影响。在未用维生素D刺激的培养物中骨钙素产生较低。单独的Dex或BMP-2处理不影响基础骨钙素水平,但与维生素D联合使用时,BMP-2可增加骨钙素产生,而Dex处理则完全抑制骨钙素产生。此外,Dex处理可大大增强PTH诱导的cAMP产生,而BMP-2对cAMP产生无影响。最后,富含BMP-2或Dex的培养物中的体外矿化大大增强。仅Dex处理可显著增加细胞增殖。总之,所描述的模型产生具有成骨细胞表型的细胞,Dex和BMP-2均可用作成骨细胞诱导剂。然而,两种处理产生的成骨细胞具有不同的表型特征,因此可以在体外对成熟成骨细胞的一些最重要基因和功能进行选择性激活。